A fully automated bionic pancreas
CAUTION: The iLet bionic pancreas is an investigational device limited by Federal (or United States) law to investigational use. Not available for sale.
Mission and Culture
Our goal as a public benefit corporation and a Certified B Corporation is to act in the best interest of the diabetes community and to make our technology accessible to as many people as possible.
The insulin-dosing software in the iLet® has been tested in 20 clinical trials over the past dozen years. The results of these studies have been published in leading peer-reviewed journals, including the New England Journal of Medicine and The Lancet.
We are developing the iLet® – a revolutionary and fully integrated wearable medical device that is designed to reduce the burden and improve the quality of diabetes care by automatically managing blood sugar levels 24/7 in people living with type 1 diabetes.
Beta Bionics in the Media
Beta Bionics and its bionic pancreas technology have been featured in stories by some of the most prestigious media organizations, including Time magazine, ABC News, and PBS.
About Beta Bionics
Beta Bionics is working to finalize development and commercialize the iLet® bionic pancreas. The iLet is a wearable medical device that is designed to autonomously control glucose in people with diabetes or other metabolic disorders.
After many years of research and clinical trials, Beta Bionics was founded in 2015 and incorporated as a Massachusetts Public Benefit Corporation. Beta Bionics is also a fully certified B Corporation.
Beta Bionics is a privately held company backed by large strategic and institutional investors.